| DB00381 | Amlodipine | For the treatment of hypertension and chronic stable angina. |
| DB00404 | Alprazolam | For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia. |
| DB00622 | Nicardipine | Used for the management of patients with chronic stable angina and for the treatment of hypertension. |
| DB01076 | Atorvastatin | May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels. |
| DB01166 | Cilostazol | For the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest). |
| DB01254 | Dasatinib | For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. |
| DB01259 | Lapatinib | Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma. |
| DB00908 | Quinidine | For the treatment of ventricular pre-excitation and cardiac dysrhythmias |
| DB00501 | Cimetidine | For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion. |
| DB00537 | Ciprofloxacin | For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure). |
| DB06589 | Pazopanib | Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
| DB01128 | Bicalutamide | For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. |
| DB00951 | Isoniazid | For the treatment of all forms of tuberculosis in which organisms are susceptible. |
| DB01406 | Danazol | For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females. |
| DB00818 | Propofol | Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. |
| DB04946 | Iloperidone | Treatment of acute schizophrenia. |
| DB08820 | Ivacaftor | When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [L768, FDA Label].
When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. |
| DB08816 | Ticagrelor | For the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation. |
| DB01764 | Dalfopristin | For the treatment of bacterial infections (usually in combination with quinupristin). |
| DB01369 | Quinupristin | For the treatment of bacterial infections (usually in combination with dalfopristin). |
| DB08827 | Lomitapide | Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C). |
| DB08815 | Lurasidone | Treatment of schizophrenia. |
| DB09073 | Palbociclib | Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. |
| DB06717 | Fosaprepitant | For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. |
| DB08909 | Glycerol Phenylbutyrate | Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. |
| DB09120 | Zucapsaicin | Indicated to be used in conjunction with oral COX-2 inhibitors or NSAIDs for the relief of severe pain in adult patients with osteoarthritis of the knee, not controlled with oral COX-2 inhibitors or NSAIDs alone, for a duration of no more than three months. |
| DB09238 | Manidipine | For the treatment of hypertension. |